[{"id":"1bd93870-384f-4902-82c2-b2d46a884d55","acronym":"CodeBreak 100","url":"https://clinicaltrials.gov/study/NCT03600883","created_at":"2021-01-17T17:12:15.060Z","updated_at":"2025-02-25T16:31:27.902Z","phase":"Phase 1/2","brief_title":"A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)","source_id_and_acronym":"NCT03600883 - CodeBreak 100","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • midazolam hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 713","initiation":"Initiation: 08/27/2018","start_date":" 08/27/2018","primary_txt":" Primary completion: 05/30/2028","primary_completion_date":" 05/30/2028","study_txt":" Completion: 05/30/2028","study_completion_date":" 05/30/2028","last_update_posted":"2025-02-07"},{"id":"277136d1-0119-42be-9629-e04f1cfca67d","acronym":"TRIDENT-1","url":"https://clinicaltrials.gov/study/NCT03093116","created_at":"2021-01-17T17:11:31.349Z","updated_at":"2025-02-25T16:31:09.380Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","source_id_and_acronym":"NCT03093116 - TRIDENT-1","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" ROS1 fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/07/2017","start_date":" 03/07/2017","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2025-02-07"},{"id":"d3bd037a-496e-40a7-bdf6-271632f38a73","acronym":"C4391001","url":"https://clinicaltrials.gov/study/NCT04557449","created_at":"2021-01-18T21:47:02.862Z","updated_at":"2025-02-25T16:45:10.545Z","phase":"Phase 1","brief_title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","source_id_and_acronym":"NCT04557449 - C4391001","lead_sponsor":"Pfizer","biomarkers":" CDKN2A • CCND1 • CD4","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["CDKN2A • CCND1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • letrozole • atirmociclib (PF-07220060) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 337","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 09/23/2026","primary_completion_date":" 09/23/2026","study_txt":" Completion: 11/23/2027","study_completion_date":" 11/23/2027","last_update_posted":"2025-02-05"},{"id":"9f4d4138-2575-46b3-8cf6-894603dcfc63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04908176","created_at":"2021-06-01T17:53:25.780Z","updated_at":"2024-07-02T16:35:07.927Z","phase":"Phase 1","brief_title":"A Drug-drug Interaction Study of Avapritinib and Midazolam","source_id_and_acronym":"NCT04908176","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 08/24/2022","start_date":" 08/24/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 04/12/2024","study_completion_date":" 04/12/2024","last_update_posted":"2024-04-23"},{"id":"67631604-169f-4968-bf77-ff9940ff3dfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04973163","created_at":"2021-07-22T17:52:57.458Z","updated_at":"2024-07-02T16:35:09.277Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation","source_id_and_acronym":"NCT04973163","lead_sponsor":"Boehringer Ingelheim","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BI 1823911 • BI 1701963 • midazolam hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/03/2021","start_date":" 08/03/2021","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2024-04-17"},{"id":"11040b56-b83a-40c8-b335-611302ea384f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03720366","created_at":"2021-01-18T18:14:03.989Z","updated_at":"2024-07-02T16:35:17.394Z","phase":"Phase 1","brief_title":"A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients","source_id_and_acronym":"NCT03720366","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib) • midazolam hydrochloride • omeprazole"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 09/22/2023","primary_completion_date":" 09/22/2023","study_txt":" Completion: 12/22/2023","study_completion_date":" 12/22/2023","last_update_posted":"2024-02-28"},{"id":"3d52136b-093e-4fc2-909c-ca05ccae6194","acronym":"AMEERA-1","url":"https://clinicaltrials.gov/study/NCT03284957","created_at":"2021-01-17T17:21:55.566Z","updated_at":"2024-07-02T16:35:19.757Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer","source_id_and_acronym":"NCT03284957 - AMEERA-1","lead_sponsor":"Sanofi","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • Verzenio (abemaciclib) • amcenestrant (SAR439859) • midazolam hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 12/29/2027","primary_completion_date":" 12/29/2027","study_txt":" Completion: 12/29/2027","study_completion_date":" 12/29/2027","last_update_posted":"2024-02-12"},{"id":"2dacc477-bfe8-43b4-9d6d-e20c6c1f10da","acronym":"","url":"https://clinicaltrials.gov/study/NCT05518799","created_at":"2022-08-29T13:02:59.122Z","updated_at":"2024-07-02T16:35:47.447Z","phase":"","brief_title":"CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid Tumours","source_id_and_acronym":"NCT05518799","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" CYP3A4","pipe":"","alterations":" ","tags":["CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/22/2021","start_date":" 04/22/2021","primary_txt":" Primary completion: 12/02/2022","primary_completion_date":" 12/02/2022","study_txt":" Completion: 12/02/2022","study_completion_date":" 12/02/2022","last_update_posted":"2023-05-22"},{"id":"e9474c39-1ad6-4925-9b2b-111e2d5459c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03420742","created_at":"2021-01-18T16:52:33.735Z","updated_at":"2024-07-02T16:35:56.843Z","phase":"Phase 1","brief_title":"A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors","source_id_and_acronym":"NCT03420742","lead_sponsor":"Takeda","biomarkers":" ROS1","pipe":" | ","alterations":" ALK positive • ROS1 positive","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 06/26/2019","start_date":" 06/26/2019","primary_txt":" Primary completion: 03/24/2020","primary_completion_date":" 03/24/2020","study_txt":" Completion: 04/29/2021","study_completion_date":" 04/29/2021","last_update_posted":"2023-01-27"},{"id":"4e483bfe-5e97-41db-b857-047a1c9033b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02857270","created_at":"2021-01-18T14:01:31.198Z","updated_at":"2024-07-02T16:36:00.102Z","phase":"Phase 1","brief_title":"A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer","source_id_and_acronym":"NCT02857270","lead_sponsor":"Eli Lilly and Company","biomarkers":" BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • NRAS mutation • BRAF V600 • RAS mutation","tags":["BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • NRAS mutation • BRAF V600 • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • gemcitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Braftovi (encorafenib) • temuterkib (LY3214996) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 210","initiation":"Initiation: 09/29/2016","start_date":" 09/29/2016","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 10/24/2022","study_completion_date":" 10/24/2022","last_update_posted":"2022-11-22"},{"id":"dee4abbf-b12e-40b5-a118-06cfe0d9020a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01655225","created_at":"2021-01-17T17:45:33.298Z","updated_at":"2024-07-02T16:36:13.381Z","phase":"Phase 1","brief_title":"A Study of LY3023414 in Participants With Advanced Cancer","source_id_and_acronym":"NCT01655225","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • CYP3A4","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Verzenio (abemaciclib) • pemetrexed • fulvestrant • letrozole • samotolisib (LY3023414) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 156","initiation":"Initiation: 07/31/2012","start_date":" 07/31/2012","primary_txt":" Primary completion: 04/04/2019","primary_completion_date":" 04/04/2019","study_txt":" Completion: 02/02/2022","study_completion_date":" 02/02/2022","last_update_posted":"2022-04-08"},{"id":"ffd7f665-f8bb-4379-a0da-85ba42059c2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04187456","created_at":"2021-01-18T20:24:44.547Z","updated_at":"2024-07-02T16:36:26.138Z","phase":"Phase 1","brief_title":"A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body","source_id_and_acronym":"NCT04187456","lead_sponsor":"AstraZeneca","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 12/27/2019","start_date":" 12/27/2019","primary_txt":" Primary completion: 03/06/2020","primary_completion_date":" 03/06/2020","study_txt":" Completion: 03/06/2020","study_completion_date":" 03/06/2020","last_update_posted":"2021-08-19"},{"id":"b4bb2d6f-d75f-4210-91cf-04cc081ab22c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03291288","created_at":"2024-02-16T08:18:36.953Z","updated_at":"2024-07-02T16:36:30.252Z","phase":"Phase 1","brief_title":"Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)","source_id_and_acronym":"NCT03291288","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" KIT","pipe":"","alterations":" ","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 02/26/2018","start_date":" 02/26/2018","primary_txt":" Primary completion: 09/26/2018","primary_completion_date":" 09/26/2018","study_txt":" Completion: 04/16/2021","study_completion_date":" 04/16/2021","last_update_posted":"2021-05-14"},{"id":"024a8f5f-32a5-41db-9bb4-e86504c3aaf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01223898","created_at":"2022-04-24T08:55:18.507Z","updated_at":"2024-07-02T16:36:37.574Z","phase":"Phase 1","brief_title":"To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib","source_id_and_acronym":"NCT01223898","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2020-12-09"},{"id":"a7da3916-76a1-444e-b30b-8aa44cb85184","acronym":"","url":"https://clinicaltrials.gov/study/NCT03955939","created_at":"2021-01-18T19:28:11.364Z","updated_at":"2024-07-02T16:36:44.594Z","phase":"Phase 1b","brief_title":"A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body","source_id_and_acronym":"NCT03955939","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3295668 • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 08/02/2019","start_date":" 08/02/2019","primary_txt":" Primary completion: 05/14/2020","primary_completion_date":" 05/14/2020","study_txt":" Completion: 05/14/2020","study_completion_date":" 05/14/2020","last_update_posted":"2020-06-01"},{"id":"ce98ee02-21d8-47cc-adbf-beb7c12bd1ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03760445","created_at":"2021-01-18T18:28:53.713Z","updated_at":"2024-07-02T16:36:51.542Z","phase":"Phase 1/2","brief_title":"HDM201 Added to CT in R/R or Newly Diagnosed AML","source_id_and_acronym":"NCT03760445","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • PML","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e midostaurin • Vyxeos (cytarabine/daunorubicin liposomal formulation) • idarubicin hydrochloride • siremadlin (HDM201) • Noxafil (posaconazole) • midazolam hydrochloride"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/15/2019","start_date":" 11/15/2019","primary_txt":" Primary completion: 07/22/2021","primary_completion_date":" 07/22/2021","study_txt":" Completion: 06/13/2023","study_completion_date":" 06/13/2023","last_update_posted":"2020-01-09"},{"id":"d7d21f29-e3c8-43ec-a65b-91985a4a991e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03333824","created_at":"2021-01-18T16:27:44.837Z","updated_at":"2024-07-02T16:37:01.370Z","phase":"Phase 1","brief_title":"Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer","source_id_and_acronym":"NCT03333824","lead_sponsor":"AstraZeneca","biomarkers":" CYP1A2","pipe":"","alterations":" ","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775) • granisetron oral • midazolam hydrochloride • omeprazole"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 01/22/2019","primary_completion_date":" 01/22/2019","study_txt":" Completion: 01/22/2019","study_completion_date":" 01/22/2019","last_update_posted":"2019-03-25"},{"id":"fc15a184-24b8-4b65-99d3-1679e83c959d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00880321","created_at":"2021-01-17T17:41:21.817Z","updated_at":"2024-07-02T16:37:16.456Z","phase":"Phase 1","brief_title":"A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors","source_id_and_acronym":"NCT00880321","lead_sponsor":"GlaxoSmithKline","biomarkers":" CXCL8","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF positive","tags":["CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tafinlar (dabrafenib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 170","initiation":"Initiation: 06/04/2009","start_date":" 06/04/2009","primary_txt":" Primary completion: 03/25/2011","primary_completion_date":" 03/25/2011","study_txt":" Completion: 03/20/2012","study_completion_date":" 03/20/2012","last_update_posted":"2017-11-13"},{"id":"2214b856-b2d7-49fd-b17c-ae1344695b73","acronym":"","url":"https://clinicaltrials.gov/study/NCT00436735","created_at":"2021-01-18T01:32:30.542Z","updated_at":"2024-07-02T16:37:17.257Z","phase":"Phase 1","brief_title":"Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors","source_id_and_acronym":"NCT00436735","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CYP3A4","pipe":"","alterations":" ","tags":["CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Viracept (nelfinavir) • midazolam hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2006","start_date":" 09/01/2006","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2017-10-06"},{"id":"67591266-4504-46d5-bc9d-cc8be38dd8fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT01001299","created_at":"2021-01-18T03:54:53.319Z","updated_at":"2024-07-02T16:37:18.894Z","phase":"Phase 1","brief_title":"A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma","source_id_and_acronym":"NCT01001299","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 11/30/2009","start_date":" 11/30/2009","primary_txt":" Primary completion: 02/29/2012","primary_completion_date":" 02/29/2012","study_txt":" Completion: 02/29/2012","study_completion_date":" 02/29/2012","last_update_posted":"2017-08-15"},{"id":"6ca623a5-286e-409d-9261-12fcda2e9229","acronym":"","url":"https://clinicaltrials.gov/study/NCT01911728","created_at":"2021-01-18T08:37:05.884Z","updated_at":"2024-07-02T16:37:20.683Z","phase":"Phase 1","brief_title":"Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates","source_id_and_acronym":"NCT01911728","lead_sponsor":"Astellas Pharma Europe B.V.","biomarkers":" CYP2C9 • CYP3A4","pipe":"","alterations":" ","tags":["CYP2C9 • CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • midazolam hydrochloride • omeprazole"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 07/25/2011","start_date":" 07/25/2011","primary_txt":" Primary completion: 02/21/2012","primary_completion_date":" 02/21/2012","study_txt":" Completion: 02/21/2012","study_completion_date":" 02/21/2012","last_update_posted":"2017-06-26"}]